Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hypogonadism × Tamoxifen × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 254 Carcinoma, Intraductal, Noninfiltrating 24 Breast Carcinoma In Situ 21 Neoplasm Metastasis 12 Breast Neoplasms, Male 12 Neoplasms 11 Ovarian Neoplasms 9 Inflammatory Breast Neoplasms 7 Glioblastoma 6 Prostatic Neoplasms 5 Central Nervous System Neoplasms 5 Gliosarcoma 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Breast Cancer Female 4 Brain Neoplasms 4 Glioma 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Astrocytoma 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Medulloblastoma 2 Liver Neoplasms 2 Hot Flashes 2 Glioma, Subependymal 2 Fibroadenoma 2

Interventions

testosterone undecanoate 4 Testosterone 3 Alendronate 2 testosterone 17 beta-cypionate 1 Triptorelin Pamoate 1 Testosterone Propionate 1 Tamoxifen 1 Standard of Care 1 Practice Guidelines as Topic 1 Orchiectomy 1 Methyltestosterone 1 Gonadotropin-Releasing Hormone 1 Gels 1 Drug Evaluation 1 Clomiphene 1 Castor Oil 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07535905 2026-04-17

REVIVE

University Health Network, Toronto

Phase 2 Not yet recruiting

Hypogonadism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡